Published in J Clin Oncol on December 06, 2010
Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother (2013) 1.44
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer (2014) 1.25
Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS). J Biomed Inform (2013) 1.10
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer (2016) 1.01
Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review. Eur J Clin Pharmacol (2013) 0.97
Rituximab-induced coronary vasospasm. Case Rep Hematol (2012) 0.96
Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles. J Biomed Inform (2014) 0.84
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget (2015) 0.81
Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles. J Biomed Inform (2015) 0.78
Treatment-related mortality with everolimus in cancer patients. Oncologist (2014) 0.76
tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs. AMIA Annu Symp Proc (2015) 0.75
Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J (2015) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol (2015) 0.75
The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf (2017) 0.75
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 2.92
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Dimorphic effects of Notch signaling in bone homeostasis. Nat Med (2008) 2.82
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol (2009) 2.66
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol (2005) 2.42
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Placebo effects in oncology. J Natl Cancer Inst (2003) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 2.16
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med (2006) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Screening trials are even more difficult than we thought they were. J Natl Cancer Inst (2002) 1.76
Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol (2007) 1.76
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials (2011) 1.71
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Blood in the belly: CT findings of hemoperitoneum. Radiographics (2007) 1.68
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer (2006) 1.59
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res (2006) 1.58
Trials in palliative treatment--have the goal posts been moved? Lancet Oncol (2008) 1.57
Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet (2009) 1.56
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48
A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care (2011) 1.47
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? J Clin Oncol (2008) 1.42
Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst (2011) 1.42
ASCO core values. J Clin Oncol (2006) 1.40
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol (2009) 1.39
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.27
Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol (2005) 1.26
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol (2008) 1.25
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer (2010) 1.22
Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol (2008) 1.22
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol (2010) 1.22
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist (2010) 1.22
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer (2014) 1.19
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer (2011) 1.16
Evaluation of treatment benefit: randomized controlled trials and population-based observational research. J Clin Oncol (2013) 1.15
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol (2008) 1.14
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer (2010) 1.14
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2007) 1.13
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol (2011) 1.13
Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol (2011) 1.11
Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol (2011) 1.10
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol (2006) 1.08
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res (2011) 1.07
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol (2013) 1.07
Ethics in oncology: consulting for the investment industry. J Clin Oncol (2007) 1.06
Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res (2006) 1.05
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol (2013) 1.05
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol (2007) 1.05
Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage (2008) 1.05
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev (2013) 1.03
Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res (2012) 1.02
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol (2002) 1.01
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs (2013) 0.99
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys (2004) 0.98
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology (2006) 0.98
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs (2011) 0.98
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol (2010) 0.97
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell (2012) 0.96
Sickle cell disease in children: differentiating osteomyelitis from vaso-occlusive crisis. Arch Pediatr Adolesc Med (2009) 0.96
Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. J Clin Oncol (2004) 0.96
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs (2013) 0.95
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer (2009) 0.95
Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun (2010) 0.94
Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol (2010) 0.94
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res (2009) 0.94
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther (2010) 0.94
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2006) 0.93
Adenoid cystic carcinoma of the larynx: a 40-year experience. Head Neck (2008) 0.93
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
Association of IL4R gene polymorphisms with asthma in Chinese populations. Hum Mutat (2007) 0.91
Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res (2005) 0.91
Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol (2004) 0.91